Beam therapeutics to present updated data from beacon phase 1/2 trial of beam-101 in sickle cell disease at american society of hematology (ash) annual meeting

Cambridge, mass., nov. 03, 2025 (globe newswire) -- beam therapeutics inc. (nasdaq: beam), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated safety and efficacy data from the beacon phase 1/2 clinical trial of beam-101 in sickle cell disease (scd) at the 67th american society of hematology (ash) annual meeting and exposition, taking place december 6-9, 2025, in orlando.
ASH Ratings Summary
ASH Quant Ranking